Identification of potential biomarkers or therapeutic targets of mesenchymal stem cells in multiple myeloma by bioinformatics analysis.

Zhi-Ran Li ^{a, b, c, 1}, Wen-Ke Cai ^{d, 1}, Qin Yang ^b, Ming-Li Shen ^b, Hua-Zhu Zhang ^b,

Qian Huang ^b, Gui-Xin Zhao ^b, Ke-Yan Chen ^b, Gong-Hao He ^{b, c, *}

^a *Institute of Pharmacy and Chemistry, Dali University, Dali 671000, China.*

^b *Department of Pharmacy, 920th Hospital of Joint Logistics Support Force, Kunming 650032, China.*

^c *Research Center of Clinical Pharmacology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650021, China.*

^d *Department of Cardio-Thoracic Surgery, 920th Hospital of Joint Logistics Support Force, Kunming 650032, China.*

Running title: Key genes and pathways of MSCs in MM

¹ These authors contributed equally to this work.

* Correspondence to: Gong-Hao He, Ph.D., 212 Dague Rd, Kunming 650032, China.

Tel: +86-871-64774793, E-mail: gonghow@hotmail.com.

Abstract

Objectives: Mesenchymal stem cells (MSCs) play important roles in multiple myeloma (MM) pathogenesis. Previous studies have discovered a group of MM-associated potential biomarkers in MSCs derived from bone marrow (BM-MSCs). However, no study of the bioinformatics analysis was conducted to explore the key genes and pathways of MSCs derived from adipose (AD-MSCs) in MM. The aim of this study was to screen potential biomarkers or therapeutic targets of AD-MSCs and BM-MSCs in MM.

Methods: The gene expression profiles of AD-MSCs (GSE133346) and BM-MSCs (GSE36474) were downloaded from Gene Expression Omnibus (GEO) database. Gene Oncology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and protein-protein interaction (PPI) network of differentially expressed genes (DEGs) were performed.

Results: A total of 456 common downregulated DEGs in two datasets were identified and the remaining DEGs in GSE133346 were further identified as specific DEGs of AD-MSCs. Furthermore, a PPI network of common downregulated DEGs was constructed and seven hub genes were identified. Importantly, cell cycle was the most significantly enrichment pathway both in AD-MSCs and BM-MSCs from MM patients.

Conclusion: We identified key genes and pathways closely related with MM progression, which may act as potential biomarkers or therapeutic targets of MM.

Keywords: bioinformatics analysis; multiple myeloma; mesenchymal stem cells;

differentially expressed genes; biomarkers.

1 Introduction

Multiple myeloma (MM) is a severe cancer of plasma cells and is characterized by unlimited proliferation of malignant plasma cells in the bone marrow [1]. It represents the second most common hematologic malignancy, inflicting approximately 13,000 mortalities in the United States in 2018 [2]. Unfortunately, the exact molecular mechanism underlying the development of MM remains unclear. Recently, it was indicated that mesenchymal stem cells (MSCs) play important roles in MM pathogenesis, which have both tumor supportive and inhibitory effects in MM [3-5]. However, further research is still needed to investigate the mechanism of MSCs in MM development and progression [3], which holds promise for finding potential drug targets and diagnostic biomarkers of MM.

MSCs reside within the connective tissue of virtually all organs, including bone marrow, muscle, thymus and adipose tissue as well [6, 7]. Nevertheless, previous studies mainly focused on bone marrow-derived mesenchymal stem cells (BM-MSCs) and have discovered a group of MM-associated potential biomarkers and key pathways by gene expression profiling analysis with microarray technology [8, 9]. However, no study of the bioinformatics analysis was conducted in other MSCs due to lacking of relevant microarray datasets. Recently, a new microarray dataset (GSE133346) [10] of adipose-derived mesenchymal stem cells (AD-MSCs) was uploaded to the Gene Expression Omnibus (GEO) database, which offers reliable data to a systematic bioinformatics analysis of AD-MSCs and is worthy of further research to better understand the role of AD-MSCs in the pathogenesis of MM. In addition,

comparing and analyzing the DEGs between AD-MSCs and BM-MSCs from the same platform would also provide more information for identifying potential specific markers of AD-MSC in MM.

Based on this background, GSE133346, along with the dataset (GSE36474) [11] of BM-MSCs deriving from the same platform, were downloaded from the GEO database for further analysis in the current study. Based on these 2 datasets, a joint bioinformatics analysis of two gene expression profiles was performed to identify MM-associated DEGs. Besides, Gene Ontology (GO) term enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and protein-protein interaction (PPI) network analysis were applied to annotate gene function and screen hub genes. The objective of this study was to identify potential crucial genes and key pathways closely related to MM both in AD-MSCs and BM-MSCs. The results of the present study may improve our understanding of the molecular mechanisms underlying MM and contribute to finding specific biomarkers of AD-MSCs in MM.

2 Materials and methods

2.1 Microarray data information and DEGs

Data of gene chips GSE133346, GSE36474 were downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). Both datasets were based on the microarray platform of Affymetrix Human Genome U133 Plus 2.0 Array (GPL570 platform) to avoid the impact of different detection platforms on the analysis. The

gene expression profile GSE133346 included AD-MSCs samples from 12 MM patients and 12 healthy controls. The GSE36474 included BM-MSCs samples from 4 MM patients and 3 healthy controls.

2.2 Identification of DEGs

The raw data in CEL files were preprocessed, including background correction, normalization and Log₂ conversion via the affy package in R software (version 3.6.0). The limma package of R was used to screen DEGs from GEO datasets. Log₂-fold change (log₂FC) was reckoned to identify genes with expression-level differences. The genes meeting the cut-off criteria of adjusted $P < 0.05$ and $|\log_2FC| > 1$ were selected as DEGs.

2.3 Functional enrichment analysis

GO analysis was carried out with the R package ggplot2. GO categories are classified into 3 groups: biological process (BP), cellular component (CC), and molecular function (MF). Another online biological tool, KOBAS 3.0 (<http://kobas.cbi.pku.edu.cn>), was used for the KEGG pathway functional enrichment. $P < 0.05$ was considered to be statistically significant.

2.4 PPI network construction and analysis of modules

The STRING database (available online: <http://string-db.org>) was used to obtain the interactions between proteins. This study performed the PPI network using overlapped DEGs in the two independent datasets (GSE133346 and GSE36474). The cut-off criterion was set as Confidence score > 0.9 . Then, the network was visualized in Cytoscape (version 3.7.1). The hub genes were identified by

Cytohubba with three ranking methods, including Degree, Maximum Neighborhood Component (MNC), and Maximal Clique Centrality (MCC). Any overlaps in the top 10 genes from three ranking methods were defined as hub genes. The Molecular Complex Detection (MCODE) in Cytoscape software was used to explore the significant modules of the PPI network. Moreover, genes in selected modules were analyzed via KOBAS to examine KEGG pathway enrichment analyses. $P < 0.05$ was considered significantly enrichment.

3 Results

3.1 Identification of DEGs in MM

There were 5605 DEGs (6 upregulated and 5599 downregulated) in GSE133346 and 1132 DEGs (139 upregulated and 993 downregulated) in GSE36474, respectively (Fig. 1A and B). Intersection analysis of the two datasets identified 456 common downregulated DEGs (Fig. 1B). For GSE133346 dataset, after removing 456 overlapped DEGs, the remaining genes were further identified as specific DEGs of AD-MSCs (6 specifically upregulated and 5143 specifically downregulated) (Fig. 1A and B). For GSE36474 dataset, after removing 456 overlapped DEGs, the rest were further identified as specific DEGs of BM-MSCs (139 specifically upregulated and 537 specifically downregulated) (Fig. 1A and B). To visualize the differential expression levels in two microarray expression profiles following standardization, the volcano plots were used for DEGs in GSE133346 (Fig. 1C) and GSE36474 (Fig. 1D).

3.2 DEGs ontology analysis in MM

To determine the biological functions of DEGs, GO analysis was applied using the ggplot2 R package. For 456 common downregulated DEGs, the top 10 most significant terms of BP, CC, and MF are shown in Table 1. The GO analysis results showed that the DEGs were particularly enriched in BP, including DNA replication, nuclear division and organelle fission. With regard to CC, the common downregulated DEGs were significantly enriched in chromosomal region, spindle, and centrosome. In addition, the common downregulated DEGs in MF were mainly enriched in chromatin binding, catalytic activity, acting on DNA, and ATPase activity. These results showed that most of the overlapped DEGs were significantly enriched in GO terms related to cell proliferation.

For AD-MSCs specific DEGs in GSE133346, a total of 6 DEGs (OLR1, AMIGO2, GPR116, BEX1, CNN1, INHBA) were found to be upregulated with only one gene (INHBA) enriched in 2 MF GO terms (i.e., transmembrane receptor protein serine/threonine kinase binding and receptor serine/threonine kinase binding) (Table 2). The 5143 specifically downregulated DEGs in AD-MSCs in BP were mostly enriched in GO terms related to metabolic process, such as positive regulation of catabolic process, positive regulation of cellular catabolic process and fatty acid metabolic process. With regard to CC and MF, these downregulated DEGs were significantly enriched in endosome membrane, early endosome and nuclear envelope (for CC) and in ubiquitin-like protein transferase activity (for MF), respectively (Table 2). For BM-MSCs specific DEGs in GSE36474, the most significant terms are shown in Supplementary Table 1.

3.3 Signaling pathway enrichment analysis

KEGG pathway analysis revealed that the 456 overlapped DEGs were significantly enriched in the cell proliferation related pathways, such as cell cycle, DNA replication, and oocyte meiosis (Fig. 2A). For 6 specifically upregulated DEGs in AD-MSCs, OLR1 gene was enriched in PPAR signaling pathway and phagosome, while INHBA gene was enriched in 3 KEGG pathways, including TGF-beta signaling pathway, signaling pathways regulating pluripotency of stem cells, and cytokine-cytokine receptor interaction. No significant pathway enrichment was found in the rest four genes (Fig. 2B). The top 10 most significant pathways of the specifically downregulated DEGs in AD-MSCs are shown in Fig. 2C. These downregulated genes were mainly involved in the metabolic pathways, pathways in cancer, and infection-related pathways (hepatitis C, hepatitis B, herpes simplex infection, and measles). For BM-MSCs specific DEGs in GSE36474, the top 10 terms of KEGG category are presented in Supplementary Fig. 1.

3.4 PPI network analysis of the DEGs and the identification of hub genes

The PPI network of 456 overlapped DEGs was constructed. After removing the genes that were not connected in the network, a total of 389 nodes and 1936 edges were obtained (Fig. 3A). Seven overlapped genes (i.e., CDK1, BUB1B, CCNB1, CDC20, MAD2L1, NDC80, and CDCA8) were identified as hub genes by the three ranking methods (Supplementary Fig. 2). Furthermore, the PPI network of seven hub genes was constructed by STRING to further understand the interaction of these genes and the results showed that they are closely associated with each other

(Supplementary Fig. 3). According to the degree of importance, we chose 3 significant modules from the PPI network complex for further analysis using Cytotype MCODE. Module 1 consisted of 26 nodes and 325 edges (Fig. 3B, Table 3), which were markedly enriched in cell cycle and oocyte meiosis. Module 2 consisted of 20 nodes and 165 edges (Fig. 3C, Table 3), which were mainly associated with cell cycle. Module 3 consisted of 31 nodes and 236 edges (Fig. 3D, Table 3), which were mostly enriched in DNA replication, cell cycle and fanconi anemia pathway. In addition, all 7 hub genes were clustered in Module 1 and most of the hub genes were associated with cell cycle pathway. These results suggested that the cell cycle pathway plays significant roles in MM. A heat map was employed to present the differences in the expression levels of the 7 hub genes in GSE133346 and GSE36474, respectively (Fig. 4). The results revealed that these genes were significantly downregulated in both AD-MSCs and BM-MSCs from MM patients.

4 Discussion

MSCs play important roles in MM pathogenesis. However the exact molecular mechanism of MSCs in MM development and progression remains unclear. Especially for AD-MSCs, no previous study of the bioinformatics analysis was conducted to explore the key genes and pathways of AD-MSCs in MM to the best of our knowledge. Therefore, the expression of genes in two microarray datasets based on MSCs (AD-MSCs and BM-MSCs) of MM patients and their normal counterparts were analyzed in current study. A total of 456 common downregulated DEGs in

AD-MSCs and BM-MSCs were identified. In addition, 6 specifically upregulated and 5143 specifically downregulated DEGs in GSE133346 were further identified as specific DEGs of AD-MSCs, while 139 specifically upregulated and 537 specifically downregulated DEGs in GSE36474 were further identified as specific DEGs of BM-MSCs. We also performed GO and KEGG pathway analysis to find crucial pathways. Furthermore, the PPI network of 456 common downregulated DEGs was constructed and 7 overlapped genes were identified as hub genes by the three ranking methods, which increased the reliability of the results compared with the method of screening hub genes by degree. The present study may help us form a comprehensive insight into the mechanisms of MM and identify potential biomarkers for prognosis and therapy of MM.

In this study, seven hub genes were identified, most of which were reported to be related to the development and progression of MM [8, 12, 13]. However, it is noteworthy that few studies directly addressed the potential effects of these genes in MSCs from MM patients. Among these hub genes, the BUB1B gene and its encoded protein (BUBR1) were reported to serve as a checkpoint for proper chromosome segregation and to prevent separation of the duplicated chromosomes in normal cells [14-16]. Previous investigations indicated that increased BUB1B expression in MM cells demonstrated drug-resistance feature, promoted MM cell proliferation and led to poor survival in MM patients [14]. However, it was interesting that, in this study, BUB1B was downregulated in both AD- and BM-MSCs from MM patients. Previous study reported that targeted inhibition of

BUBR1 expression in MSCs significantly reduced the potential to differentiate and led to cellular senescence [17]. On one hand, for AD-MSCs, myeloma cells can corrupt senescent AD-MSCs and impair their anti-tumor activity [18]. On the other hand, for BM-MSCs, senescent cells were also reported to exacerbate the progression of MM [11, 19]. Therefore, cellular senescence of both AD-MSCs and BM-MSCs may increase the proliferation of MM cell and led to the deterioration of the disease. These findings might reveal a novel function of BUB1B in MSCs and targeting BUB1B might be a potential therapeutic strategy for MM patients.

Moreover, as a cell proliferation-associated gene, CDK1 was reported to be an important driver for MM disease progression [20, 21]. Besides, previous studies also showed that the downregulation of CDK1 was related to osteogenic differentiation disorder and senescence of MSCs [22-24]. In addition, it was interesting that expression knockdown of CDK1 resulted in significantly increased adipogenic differentiation of AD-MSCs [25]. Therefore, abnormal expression of CDK1 in MSCs may also result in dysfunction of MSCs and lead to progression of MM although further functional studies are still needed.

As for MAD2L1, CCNB1, CDCA8, CDC20 and NDC80, these hub genes also played important roles in regulating cell proliferation, apoptosis and chromosome stability according to pervious reports [26, 27]. The irregular expression of these genes in cells often accompanied with cell proliferation disorders and chromosome instability [28-30]. As it was reported that genome instability and low proliferative capacity were key causes of MSCs senescence [24, 31, 32], downregulation of these

identified hub genes in MSCs may also eventually lead to the progression of MM.

Importantly, according to KEGG pathway analysis, we found that common downregulated DEGs, the genes in top three modules, and the hub genes were all primarily enriched in the cell cycle that was documented previously as a factor to start the process of MM and was closely related to patients' survival [13]. These data were in accordance with previous studies, which indicated that aberrant cell cycle pathway of MSCs marked with S phase arrest and reduced proliferation of MSCs played crucial roles in development of MM [11] and other cancers [33]. In addition, previous study also found that the function of cell cycle of MSCs was impaired in MM patients, leading the MSCs to enter into an early cellular senescence process [9] and to participate in progression and relapse of MM [11, 18]. Therefore, impaired cell cycle pathway of MSCs contributed directly or indirectly to the pathophysiological progress of MM. Further unravelling of the molecular mechanism about this pathway and relevant genes may be necessary for future efforts.

In addition, the present analyses identified 6 DEGs that were specifically upregulated in AD-MSCs and may serve as promising diagnostic and therapeutic targets in MM. However, it is of note that the effects and potential mechanisms of these genes in MSCs were rarely investigated so far. A small number of studies demonstrated the important roles of INHBA and OLR1 in MSCs. INHBA was a key regulator in the maintenance of pluripotency of stem cells [34], including AD-MSCs [35]. Previous study showed that INHBA overexpression was related to high chondrogenic and osteogenic potential of MSCs [34], which was further suggested to

suppress proliferation of MM plasma cells [36]. Therefore, upregulation of INHBA in AD-MSCs may also enhance osteogenic differentiation through osteogenic pathway (TGF-beta signaling pathway) and pluripotency-regulating pathway of stem cells, which might exert anti-tumor effects in MM and may be a promising therapeutic target in MM. As for OLR1 gene, it is a novel PPAR- γ target gene playing a critical role in the regulation of adipocyte lipid metabolism [37]. High level of OLR1 expression was linked to obesity and dyslipidemia [37-39]. PPAR- γ was well established as a prime inducer of adipogenesis, which was demonstrated to regulate the differentiation of MSCs into adipocytes [40]. Based on these previous findings, overexpressed OLR1 in AD-MSCs might also result in increased adipogenic differentiation by PPAR signaling pathway, which would eventually enhance MM cell growth [41]. As for the rest 4 identified DEGs (i.e., GPR116, BEX1, AMIGO2 and CNN1), it is interesting that currently no studies were found to investigate their roles in AD-MSCs so far as we know. These genes might hence be novel potential diagnostic and therapeutic biomarkers in MM although further functional research is still required.

Furthermore, this study also identified 5143 specifically downregulated DEGs in AD-MSCs. Among these genes, IL-1R2 gene (IL1R2) and ZNF45 were demonstrated to be expressed uniquely in AD-MSCs but not in BM-MSCs [42]. Anti-inflammatory cytokine IL-1R2 is a specific and natural inhibitor of IL-1 and was reported to regulate cell metabolism and to respond to immune inflammation induced by many cytokines [43]. Previous studies showed that IL-1 inhibited chondrogenesis

of adult AD-MSCs [44]. Therefore, downregulated IL1R2 in AD-MSCs may weaken its inhibitory effect on IL-1 and result in chondrogenic disorder of AD-MSCs and development of MM. As for ZNF45, this gene is a zinc finger gene, which was involved in transcription control in AD-MSCs [42]. Previous studies demonstrated that many zinc finger genes/proteins functioned as key transcriptional regulators in osteoblast differentiation of MSCs [45-47]. So, changes in the expression of ZNF45 in AD-MSCs may also lead to dysfunction of osteogenic differentiation of AD-MSCs. These two genes may be important markers of AD-MSCs in MM patients and promising therapeutic targets for MM. Further research on the underlying molecular mechanisms of these two genes in AD-MSCs may supply new insights for the treatment of MM.

In conclusion, through a series of comprehensive analysis of bioinformatics, several crucial genes and certain associated pathways were successfully screened. Our study suggested that the cell cycle pathway was closely related to the development of MM. Seven hub genes may be the potential diagnostic and therapeutic biomarkers both in AD-MSCs and BM-MSCs from MM patients. In addition, IL1R2 and ZNF45 might act as important markers of AD-MSCs in MM. These findings would provide a comprehensive insight into the pathogenesis of MM and hold promise for finding potential drug targets and diagnostic biomarkers.

Author Contributions

Study conceive and design (ZRL, WKC, GHH), acquisition of subjects and data (ZRL,

WKC, GHH), analysis and interpretation of data (ZRL, WKC, QY, MLS, HZZ, QH, GXZ, KYC, GHH), and preparation of manuscript (ZRL, WKC, QY, MLS, HZZ, QH, GXZ, KYC, GHH).

Acknowledgements

Not applicable.

Founding

This work was supported by grants from the National Science Foundation of China (NO. 81460560 and 81960664) and the Applied Basic Research Program of Yunnan Province of China (NO. 2017FB134).

Conflict of Interest

No conflict of interest declared.

References

- [1] Palumbo, A., Anderson, K., 2011. Multiple myeloma. *N. Engl. J. Med.* 364 (11), 1046-1060. <https://doi.org/10.1056/NEJMra1011442>.
- [2] Campbell, K.S., Cohen, A.D., Pazina, T., 2018. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. *Front Immunol.* 9, 2551. <https://doi.org/10.3389/fimmu.2018.02551>.
- [3] Reagan, M.R., Ghobrial, I.M., 2012. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. *Clin Cancer Res.* 18 (2), 342-349. <https://doi.org/10.1158/1078-0432.CCR-11-2212>.
- [4] Atsuta, I., Liu, S., Miura, Y., Akiyama, K., Chen, C., An, Y., Shi, S., Chen, F.M., 2013. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway. *Stem Cell Res Ther.* 4 (5), 111. <https://doi.org/10.1186/scrt322>.
- [5] Ciavarella, S., Caselli, A., Tamma, A.V., Savonarola, A., Loverro, G., Paganelli, R., Tucci, M., Silvestris, F., 2015. A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression. *Stem Cells Dev.* 24 (12), 1457-1470. <https://doi.org/10.1089/scd.2014.0254>.
- [6] Zuk, P.A., Zhu, M., Mizuno, H., Huang, J., Futrell, J.W., Katz, A.J., Benhaim, P., Lorenz, H.P., Hedrick, M.H., 2001. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng.* 7 (2), 211-228. <https://doi.org/10.1089/107632701300062859>.

- [7] da Silva Meirelles, L., Chagastelles, P.C., Nardi, N.B., 2006. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. *J Cell Sci.* 119, 2204-2213. <https://doi.org/10.1242/jcs.02932>.
- [8] Wang, X.G., Peng, Y., Song, X.L., Lan, J.P., 2016. Identification potential biomarkers and therapeutic agents in multiple myeloma based on bioinformatics analysis. *Eur Rev Med Pharmacol Sci.* 20 (5), 810-817.
- [9] Fernando, R.C., Mazzotti, D.R., Azevedo, H., Sandes, A.F., Rizzatti, E.G., de Oliveira, M.B., Alves, V.L.F., Eugênio, A.I.P., de Carvalho, F., Dalboni, M.A., Martins, D.C., Colleoni, G.W.B., 2019. Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism. *Sci Rep.* 9 (1), 1056. <https://doi.org/10.1038/s41598-018-38314-8>.
- [10] Espagnolle, N., Hebraud, B., Descamps, J.G., Gadelorge, M., Joubert, M.V., Ferreira, L.D.S., Roussel, M., Huynh, A., Sensébé, L., Casteilla, L., Attal, M., Avet-Loiseau, H., Deschaseaux, F., Bourin, P., Corre, J., 2020. Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells. *Stem Cells Int.* 2020, 4173578. <https://doi.org/10.1155/2020/4173578>.
- [11] André, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., Lagneaux, L., 2013. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. *PLoS One.* 8 (3), e59756. <https://doi.org/10.1371/journal.pone.0059756>.

- [12] Chen, H., Chai, W., Li, B., Ni, M., Zhang, G.Q., Liu, H.W., Zhang, Z., Chen, J.Y., Zhou, Y.G., Wang, Y., 2015. Effects of β -catenin on differentially expressed genes in multiple myeloma. *J Huazhong Univ Sci Technolog Med Sci.* 35 (4), 546-552. <https://doi.org/10.1007/s11596-015-1468-4>.
- [13] Zhu, F.X., He, Y.C., Zhang, J.Y., Wang, H.F., Zhong, C., Wang, X.T., 2019. Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma. *Med Sci Monit.* 25, 3247-3255. <https://doi.org/10.12659/MSM.913970>.
- [14] Yang, Y., Gu, C., Luo, C., Li, F., Wang, M., 2015. BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis. *Med Oncol.* 32 (3), 81. <https://doi.org/10.1007/s12032-015-0542-x>.
- [15] Cai, Y., Mei, J., Xiao, Z., Xu, B., Jiang, X., Zhang, Y., Zhu, Y., 2019. Identification of five hub genes as monitoring biomarkers for breast cancer metastasis in silico. *Hereditas.* 156, 20. <https://doi.org/10.1186/s41065-019-0096-6>.
- [16] Yan, X., Liu, X.P., Guo, Z.X., Liu, T.Z., Li, S., 2019. Identification of Hub Genes Associated With Progression and Prognosis in Patients With Bladder Cancer. *Front Genet.* 10, 408. <https://doi.org/10.3389/fgene.2019.00408>.
- [17] Lee, J., Lee, C.G., Lee, K.W., Lee, C.W., 2009. Cross-talk between BubR1 expression and the commitment to differentiate in adipose-derived mesenchymal stem cells. *Exp Mol Med.* 41 (12), 873-879. <https://doi.org/10.3858/emm.2009.41.12.093>.
- [18] Özcan, S., Alessio, N., Acar, M.B., Toprak, G., Gönen, Z.B., Peluso, G., Galderisi, U., 2015. Myeloma cells can corrupt senescent mesenchymal stromal cells and impair

their anti-tumor activity. *Oncotarget*. 6 (37), 39482-39492.

<https://doi.org/10.18632/oncotarget.5430>.

[19] Raaijmakers, M.H., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J.A., Ebert, B.L., Al-Shahrour, F., Hasserjian, R.P., Scadden, E.O., Aung, Z., Matza, M., Merckenslager, M., Lin, C., Rommens, J.M., Scadden, D.T., 2010. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. *Nature*. 464 (7290), 852-857. <https://doi.org/10.1074/jbc.M115.683052>.

[20] Liu, Q., Tao, B., Liu, G., Chen, G., Zhu, Q., Yu, Y., Yu, Y., Xiong, H., 2016. Thromboxane A2 Receptor Inhibition Suppresses Multiple Myeloma Cell Proliferation by Inducing p38/c-Jun N-terminal Kinase (JNK) Mitogen-activated Protein Kinase (MAPK)-mediated G2/M Progression Delay and Cell Apoptosis. *J Biol Chem*. 291 (9), 4779-4792. <https://doi.org/10.1074/jbc.M115.683052>.

[21] Gao, M., Li, B., Sun, X., Zhou, Y., Wang, Y., Tompkins, V.S., Xu, Z., Indima, N., Wang, H., Xiao, W., Gao, L., Chen, G., Wu, H., Wu, X., Kong, Y., Xie, B., Zhang, Y., Chang, G., Hu, L., Yang, G., Dai, B., Tao, Y., Zhu, W., Shi, J., 2017. Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma. *Theranostics*. 7 (15), 3690-3699. <https://doi.org/10.7150/thno.18345>.

[22] Wei, Y., Chen, Y.H., Li, L.Y., Lang, J., Yeh, S.P., Shi, B., Yang, C.C., Yang, J.Y., Lin, C.Y., Lai, C.C., Hung, M.C., 2011. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. *Nat Cell Biol*. 13 (1), 87-94. <https://doi.org/10.1038/ncb2139>.

- [23] Garg, P., Mazur, M.M., Buck, A.C., Wandtke, M.E., Liu, J., Ebraheim, N.A., 2017. Prospective Review of Mesenchymal Stem Cells Differentiation into Osteoblasts. *Orthopaedic Surgery*. 9 (1), 13-19. <https://doi.org/10.1111/os.12304>.
- [24] Kim, J., Kim, Y., Choi, H., Kwon, A., Jekarl, D.W., Lee, S., Jang, W., Chae, H., Kim, J.R., Kim, J.M., Kim, M., 2018. Ubiquitin C decrement plays a pivotal role in replicative senescence of bone marrow mesenchymal stromal cells. *Cell Death Dis*. 9 (2), 139. <https://doi.org/10.1038/s41419-017-0032-5>.
- [25] Marquez, M.P., Alencastro, F., Madrigal, A., Jimenez, J.L., Blanco, G., Gureghian, A., Keagy, L., Lee, C., Liu, R., Tan, L., Deignan, K., Armstrong, B., Zhao, Y., 2017. The Role of Cellular Proliferation in Adipogenic Differentiation of Human Adipose Tissue-Derived Mesenchymal Stem Cells. *Stem Cells Dev*. 26 (21), 1578-1595. <https://doi.org/10.1089/scd.2017.0071>.
- [26] Liao, Y., Yin, G., Wang, X., Zhong, P., Fan, X., Huang, C., 2019. Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis. *Oncol Lett*. 18 (4), 3723-3733. <https://doi.org/10.3892/ol.2019>.
- [27] Bu, Y., Shi, L., Yu, D., Liang, Z., Li, W., 2019. CDCA8 is a key mediator of estrogen-stimulated cell proliferation in breast cancer cells. *Gene*. 703, 1-6. <https://doi.org/10.1016/j.gene.2019.04.006>.
- [28] Bi, Y., Chen, S., Jiang, J., Yao, J., Wang, G., Zhou, Q., Li, S., 2018. CDCA8 expression and its clinical relevance in patients with bladder cancer. *Medicine (Baltimore)*. 97 (34), e11899. <https://doi.org/10.1097/MD.00000000000011899>.

- [29] Dong, S., Huang, F., Zhang, H., Chen, Q., 2019. Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma. *Biosci Rep.* 39 (2). <https://doi.org/10.1042/BSR20182306>.
- [30] Peng, W.X., Gao, C.H., Huang, G.B., 2019. High throughput analysis to identify key gene molecules that inhibit adipogenic differentiation and promote osteogenic differentiation of human mesenchymal stem cells. *Exp Ther Med.* 17 (4), 3021-3028. <https://doi.org/10.3892/etm.2019.7287>.
- [31] Estrada, J.C., Torres, Y., Benguría, A., Dopazo, A., Roche, E., Carrera-Quintanar, L., Pérez, R.A., Enríquez, J.A., Torres, R., Ramírez, J.C., Samper, E., Bernad, A., 2013. Human mesenchymal stem cell-replicative senescence and oxidative stress are closely linked to aneuploidy. *Cell Death Dis.* 4, e691. <https://doi.org/10.1038/cddis.2013.211>.
- [32] Capelli, C., Pedrini, O., Cassina, G., Spinelli, O., Salmoiraghi, S., Golay, J., Rambaldi, A., Giussani, U., Introna, M., 2014. Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. *Haematologica.* 99 (6), e94-97. <https://doi.org/10.3324/haematol.2014.104711>.
- [33] Xu, X., Zhang, X., Wang, S., Qian, H., Zhu, W., Cao, H., Wang, M., Chen, Y., Xu, W., 2011. Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and adjacent non-cancerous tissues. *J Cancer Res Clin Oncol.* 137 (3), 495-504. <https://doi.org/10.1007/s00432-010-0908-6>.

- [34] Djouad, F., Jackson, W.M., Bobick, B.E., Janjanin, S., Song, Y., Huang, G.T., Tuan, R.S., 2010. Activin A expression regulates multipotency of mesenchymal progenitor cells. *Stem Cell Res Ther.* 1 (2), 11. <https://doi.org/10.1186/scrt11>.
- [35] Heo, J.S., Choi, Y., Kim, H.S., Kim, H.O., 2016. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. *Int J Mol Med.* 37 (1), 115-125. <https://doi.org/10.3892/ijmm.2015.2413>.
- [36] Cho, Y.K., Kim, S.I., Ha, K.Y., Kim, Y.H., Park, H.Y., Min, C.K., 2019. Increased Osteoblastic Activity Suppressed Proliferation of Multiple Myeloma Plasma Cells. *Spine (Phila Pa 1976).* 44 (7), E384-E392. <https://doi.org/10.1097/BRS.0000000000002873>.
- [37] Chui, P.C., Guan, H.P., Lehrke, M., Lazar, M.A., 2005. PPAR γ regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. *J Clin Invest.* 115 (8), 2244-2256. <https://doi.org/10.1172/JCI24130>.
- [38] Khaidakov, M., Mitra, S., Kang, B.Y., Wang, X., Kadlubar, S., Novelli, G., Raj, V., Winters, M., Carter, W.C., Mehta, J.L., 2011. Oxidized LDL Receptor 1 (OLR1) as a Possible Link between Obesity, Dyslipidemia and Cancer. *PLoS ONE.* 6 (5), e20277. <https://doi.org/10.1371/journal.pone.0020277>.
- [39] Tian, K., Ogura, S., Little, P.J., Xu, S.W., Sawamura, T., 2019. Targeting LOX α 1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. *Ann N Y Acad Sci.* 1443 (1), 34-53. <https://doi.org/10.1111/nyas.13984>.

- [40] Li, Y., Jin, D., Xie, W., Wen, L., Chen, W., Xu, J., Ding, J., Ren, D., 2018. PPAR- γ and Wnt regulate the differentiation of MSCs into adipocytes and osteoblasts respectively. *Curr Stem Cell Res Ther.* 13 (3), 185-192. <https://doi.org/10.2174/1574888X12666171012141908>.
- [41] Adamik, J., Roodman, G.D., Galson, D.L., 2019. Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease. *JBMR Plus.* 3 (3), e10183. <https://doi.org/10.1002/jbm4.10183>.
- [42] Noël, D., Caton, D., Roche, S., Bony, C., Lehmann, S., Casteilla, L., Jorgensen, C., Cousin, B., 2008. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. *Exp Cell Res.* 314 (7), 1575-1584. <https://doi.org/10.1016/j.yexcr.2007.12.022>.
- [43] Peters, V.A., Joesting, J.J., Freund, G.G., 2013. IL-1 receptor 2 (IL-1R2) and its role in immune regulation. *Brain Behav Immun.* 32, 1-8. <https://doi.org/10.1016/j.bbi.2012.11.006>.
- [44] Ousema, P.H., Moutos, F.T., Estes, B.T., Caplan, A.I., Lennon, D.P., Guilak, F., Weinberg, J.B., 2012. The inhibition by interleukin 1 of MSC chondrogenesis and the development of biomechanical properties in biomimetic 3D woven PCL scaffolds. *Biomaterials.* 33 (35), 8967-8974. <https://doi.org/10.1016/j.biomaterials.2012.08.045>.
- [45] Liu, T.M., Guo, X.M., Tan, H.S., Hui, J.H., Lim, B., Lee, E.H., 2011. Zinc-finger protein 145, acting as an upstream regulator of SOX9, improves the differentiation potential of human mesenchymal stem cells for cartilage regeneration and repair. *Arthritis Rheum.* 63 (9), 2711-2720. <https://doi.org/10.1002/art.30430>.

- [46] Twine, N.A., Harkness, L., Kassem, M., Wilkins, M.R., 2016. Transcription factor ZNF25 is associated with osteoblast differentiation of human skeletal stem cells. BMC Genomics. 17 (1), 872. <https://doi.org/10.1186/s12864-016-3214-0>.
- [47] Chiarella, E., Aloisio, A., Scicchitano, S., Lucchino, V., Montalcini, Y., Galasso, O., Greco, M., Gasparini, G., Mesuraca, M., Bond, H.M., Morrone, G., 2018. ZNF521 Represses Osteoblastic Differentiation in Human Adipose-Derived Stem Cells. Int J Mol Sci. 19 (12), 4095. <https://doi.org/10.3390/ijms19124095>.

Table 1. GO enrichment analysis of common downregulated DEGs.

Category	Term	Description	Count	P value
BP	GO:0006260	DNA replication	53	8.26E-39
BP	GO:0140014	Mitotic nuclear division	46	1.04E-32
BP	GO:0006261	DNA-dependent DNA replication	36	1.22E-31
BP	GO:0000280	Nuclear division	51	1.70E-29
BP	GO:0048285	Organelle fission	51	2.28E-27
BP	GO:0000819	Sister chromatid segregation	35	3.08E-27
BP	GO:0007059	Chromosome segregation	43	1.41E-26
BP	GO:0000070	Mitotic sister chromatid segregation	32	3.23E-26
BP	GO:0098813	Nuclear chromosome segregation	38	3.41E-25
BP	GO:0044786	Cell cycle DNA replication	22	2.15E-23
CC	GO:0098687	Chromosomal region	46	1.00E-25
CC	GO:0005819	spindle	41	1.23E-21
CC	GO:0000793	Condensed chromosome	33	2.16E-21
CC	GO:0000775	chromosome, centromeric region	29	3.08E-18
CC	GO:0000776	kinetochore	23	7.94E-16
CC	GO:0000779	Condensed chromosome, centromeric region	21	2.52E-15
CC	GO:0000777	Condensed chromosome kinetochore	20	4.57E-15
CC	GO:0000922	Spindle pole	23	2.26E-14
CC	GO:0005813	centrosome	39	2.58E-14
CC	GO:0005657	Replication fork	13	2.46E-11
MF	GO:0003697	single-stranded DNA binding	12	3.70E-07
MF	GO:0003684	Damaged DNA binding	10	4.21E-07
MF	GO:0140097	Catalytic activity, acting on DNA	15	7.16E-07
MF	GO:0043142	single-stranded DNA-dependent ATPase activity	5	2.73E-06
MF	GO:0035173	Histone kinase activity	5	6.68E-06
MF	GO:0008094	DNA-dependent ATPase activity	9	1.85E-05
MF	GO:0003682	Chromatin binding	22	1.41E-04
MF	GO:0004386	Helicase activity	10	3.61E-04
MF	GO:0042623	ATPase activity, coupled	13	7.04E-04
MF	GO:0016887	ATPase activity	15	8.57E-04

GO: Gene Ontology; DEGs: differentially expressed genes; BP: biological process; CC: cell component; MF: molecular function.

Table 2. GO enrichment analysis of the specifically up- and downregulated DEGs in AD-MSCs.

Category	Term	Description	Count	P value
Upregulated				
MF	GO:0070696	transmembrane receptor protein serine/threonine kinase binding	1	2.94E-03
MF	GO:0033612	receptor serine/threonine kinase binding	1	4.71E-03
Downregulated				
BP	GO:0071346	cellular response to interferon-gamma	59	8.57E-07
BP	GO:0002685	regulation of leukocyte migration	68	1.29E-06
BP	GO:0009896	positive regulation of catabolic process	123	1.80E-06
BP	GO:1990778	protein localization to cell periphery	92	2.26E-06
BP	GO:0002062	chondrocyte differentiation	41	2.68E-06
BP	GO:0034504	protein localization to nucleus	77	3.40E-06
BP	GO:0002687	positive regulation of leukocyte migration	48	3.47E-06
BP	GO:0031331	positive regulation of cellular catabolic process	107	8.22E-06
BP	GO:0043330	response to exogenous dsRNA	18	9.18E-06
BP	GO:0006631	fatty acid metabolic process	106	1.07E-05
CC	GO:0005769	early endosome	109	1.12E-06
CC	GO:0010008	endosome membrane	138	4.84E-06
CC	GO:0043202	lysosomal lumen	36	9.55E-05
CC	GO:0045177	apical part of cell	107	1.02E-04
CC	GO:0005775	vacuolar lumen	56	2.29E-04
CC	GO:0005635	nuclear envelope	118	3.13E-04
CC	GO:0000151	ubiquitin ligase complex	69	3.61E-04
CC	GO:0031253	cell projection membrane	92	4.34E-04
CC	GO:0031252	cell leading edge	108	5.26E-04
MF	GO:0019787	ubiquitin-like protein transferase activity	106	2.20E-05

GO: Gene Ontology; DEGs: differentially expressed genes; BP: biological process;

CC: cell component; MF: molecular function; AD-MSCs: adipose-derived mesenchymal stem cells.

Table 3. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the differentially expressed genes (DEGs) in top 3 modules.

Module	Term	Description	Count	P-value	Genes
Module 1	hsa04110	Cell cycle	5	1.06E-08	BUB1B, CDK1, CDC20, MAD2L1, CCNB1
Module 1	hsa04114	Oocyte meiosis	4	8.37E-07	CDK1, CDC20, MAD2L1, CCNB1
Module 1	hsa04914	Progesterone-mediated oocyte maturation	3	2.71E-05	CDK1, MAD2L1, CCNB1
Module 1	hsa05166	HTLV-I infection	3	4.54E-04	CDC20, MAD2L1, BUB1B
Module 1	hsa04115	p53 signaling pathway	2	7.75E-04	CDK1, CCNB1
Module 2	hsa04110	Cell cycle	2	1.82E-03	TTK, CCNA2
Module 2	hsa00480	Glutathione metabolism	1	2.63E-02	RRM2
Module 2	hsa04115	p53 signaling pathway	1	3.46E-02	RRM2
Module 2	hsa04914	Progesterone-mediated oocyte maturation	1	4.86E-02	CCNA2
Module 3	hsa03030	DNA replication	11	1.46E-25	MCM5, RPA2, RPA3, MCM3, RFC2, RFC3, RFC4, POLA1, PRIM1, FEN1, RFC5
Module 3	hsa03460	Fanconi anemia pathway	7	4.01E-14	RPA2, RPA3, RMI2, BRCA2, BLM, RMI1, HES1
Module 3	hsa03430	Mismatch repair	6	6.27E-14	RPA2, RPA3, RFC2, RFC3, RFC4, RFC5
Module 3	hsa03420	Nucleotide excision repair	6	2.99E-12	RPA2, RPA3, RFC2, RFC3, RFC4, RFC5
Module 3	hsa04110	Cell cycle	7	8.78E-12	MCM5, CDC6, MCM3, CDC7, ORC6, DBF4, ORC17

Fig. 1. Identification of differentially expressed genes (DEGs) in two profile datasets.

Venn analysis of DEGs: (A) Common upregulated DEGs, (B) common downregulated DEGs. Respective volcano plot of the two datasets: (C) GSE133346, (D) GSE36474. The red points represent upregulated genes with $\log_2FC > 1$ and adjusted $P < 0.05$. The blue points represent downregulated genes with $\log_2FC < -1$ and adjusted $p < 0.05$.

Fig. 2. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of differentially expressed genes (DEGs): (A) The top 10 significant KEGG pathways of common downregulated DEGs. (B) KEGG pathway enrichment analysis of specifically upregulated DEGs in adipose-derived mesenchymal stem cells (AD-MSCs). (C) The top 10 significant KEGG pathways of specifically downregulated DEGs in AD-MSCs.

Fig. 3. The protein-protein interaction (PPI) network and modules identified: (A) PPI network analysis of overlapped differentially expressed genes (DEGs). Nodes with higher degree are displayed in larger size and dark blue color and nodes with lower degree are shown in smaller size and bright orange color. The edge size is consistent with the coexpression intensity. Modules 1 (B), Modules 2 (C) and Modules 3 (D) were identified in PPI. The blue circle indicates the downregulated DEGs, the top 7 hub genes are highlighted with yellow circles.

Fig. 4. Hub gene expression heat maps among the 2 databases: (A) GSE133346, (B) GSE36474. Red color represents high expression level, and blue color represents low expression level.